Evolus reports record Q4 revenue $61.0M (+40% YoY); guides to Q4 2024 profitability

Evolus, Inc.

Full-year 2023 net revenue $202.1M (+36% YoY); Q4 record $61.0M (+40% YoY).
Q4 non-GAAP operating loss narrowed to $3.7M from $5.7M in Q3; full-year non-GAAP loss down 48% to $23.4M.
Reaffirms 2024 revenue guidance $255-265M (26-31% growth); expects positive non-GAAP operating income in Q4 2024 and full year 2025.
Added 840+ new Jeuveau accounts in Q4, total >12,400; loyalty program grew 55% to 750,000 members.
Plans to file PMA for first two Evolysse fillers by mid-2024; targets at least $700M net revenue by 2028.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Evolus, Inc. reported the quarter and year ended December 31, 2023 results: revenue $61.0 million. Guidance reaffirmed.

Period: the quarter and year ended December 31, 2023
Revenue: $61.0 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

of $2 Million Compared to Q3 • Full-Year 2023 Operating Expense of $163.9 Million in Alignment with Guidance Range of $160 Million to $165 Million • Global Net Revenue Record of $61.0 Million for the Fourth Quarter and $202.1 Million Full-Year 2023, Representing 40% and 36% Growth Over the Prior Year; These Results Are Unchanged from the Preliminary Results Reported

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

Evolus, Inc. filing history →

Source: SEC EDGAR

accession 0001570562-24-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.